山东威高药业

Shandong Weigao Pharmaceutical is a core subsidiary of the Weigao Group, specializing in the research, development, and manufacturing of pharmaceutical products with a strong focus on nephrology. The company is a leading provider of peritoneal dialysis solutions and erythropoietin (EPO) for the treatment of chronic kidney disease and associated anemia in China. Beyond nephrology, its portfolio includes clinical nutrition, anesthesia, and anti-infective medications. Weigao Pharmaceutical operates advanced GMP-certified manufacturing bases and maintains a robust R&D pipeline aimed at innovative drug delivery and specialized therapeutic areas. The company benefits from the broader Weigao Group's extensive distribution network and medical device synergy. It is recognized as a key player in the Chinese healthcare market, particularly for its integrated approach to blood purification and renal care.